Innovent Announces First Patient Dosed in a Phase 1b Clinical Trial of Sintilimab plus Surufatinib in Advanced Malignancies in China

July 7,2020

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced that the first patient has been successfully dosed in a Phase 1b clinical trial (CIBI391A101) of TYVYT® (sintilimab injection) plus surufatinib in China.

CIBI391A101 is a Phase 1b clinical study conducted in China to evaluate sintilimab plus surufatinib in the treatment of patients with advanced malignancies. The primary objectives of the study are to evaluate the safety, tolerability, and initial anti-tumor efficacy of surufatinib in combination with TYVYT® (sintilimab injection).

Dr. Hui Zhou, Vice President and Head of Oncology Strategy and Medical Sciences of Innovent, stated: "Sintilimab is an anti-PD-1 monoclonal antibody drug jointly developed by Innovent and Lilly. It has been proven effective and safe in a variety of tumors including classic Hodgkin lymphoma, lung cancer, esophageal cancer, etc. Surufatinib selectively inhibits the tyrosine kinase activity associated with VEGFR and FGFR, which both inhibit angiogenesis and CSF-1R, which regulates tumor-associated macrophages. Therefore, the combination of sintilimab and surufatinib may result in synergistic anti-tumor activity, and we are looking forward to the positive results of the clinical trials of sintilimab plus surufatinib, and hope the therapy could benefit more patients."